Abstract
Non–muscle-invasive bladder cancer (NMIBC) is heterogeneous, but current diagnostic and treatment strategies rely primarily on clinical parameters, lacking individualization to tumor and host genetics and biology. The heterogeneity of NMIBCs is derived from mutations, mutation signatures, chromosomal loss, and disruption of molecular pathways, which ultimately affects tumor progression, recurrence, and responsiveness to intravesical and systemic chemotherapy. Although research is still underway, advances in sequencing technology, insight into differential bacillus Calmette-Guérin responses, and new investigational treatment targets will soon offer clinicians new, precision-based tools to risk stratify and determine treatment regimens for future patients with bladder cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 35-46 |
| Number of pages | 12 |
| Journal | Urologic Clinics of North America |
| Volume | 47 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2020 |
Funding
Disclosure: L.F. Cooley and K.A. McLaughlin have nothing to disclose. J.J. Meeks is a consultant for Ferring and Astra Zeneca, receives honoraria from Janssen and Cold Genesys, and receives research funding from Epizyme, Abbvie, and Tesaro, with clinical trial support from Merck.Funding: J.J. Meeks is supported by Department of Veterans Affairs (BX003692) and Department of Defense (W81XWH-18-0257) and an award from the John P. Hanson Foundation for Cancer Research (Milwaukee, WI).
Keywords
- BCG
- Bladder cancer
- Genomics
- Immunotherapy
- Mutation
ASJC Scopus subject areas
- Urology
